Middle Molecular Uremic Toxin and Blood Purification Therapy

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Feb 10

PMID 38337341

Authors

Hideki Kawanishi

Affiliations

Soon will be listed here.

Abstract

The purpose of blood purification therapy is to remove uremic toxins, and middle molecules (MMs) are a specific target. An MM is defined as a solute that passes through the glomerulus with a molecular weight in the range of 0.5-58 kDa, and new classifications of "small-middle 0.5-15 kDa," "medium-middle 15-25 kDa," and "large-middle 25-58 kDa" were proposed. In Japan, the removal of α1-microglobulin (αMG) in the large-middle range has been the focus, but a new theory of removal has been developed, emphasizing the antioxidant effect of αMG as a physiological function. Clinical proof of this mechanism will lead to further development of blood purification therapies.

References

Eknoyan G, Beck G, Cheung A, Daugirdas J, Greene T, Kusek J . Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347(25):2010-9. DOI: 10.1056/NEJMoa021583. View

Furuyoshi S, Nakatani M, Taman J, Kutsuki H, Takata S, Tani N . New adsorption column (Lixelle) to eliminate beta2-microglobulin for direct hemoperfusion. Ther Apher. 1999; 2(1):13-7. DOI: 10.1111/j.1744-9987.1998.tb00067.x. View

Rosner M, Reis T, Husain-Syed F, Vanholder R, Hutchison C, Stenvinkel P . Classification of Uremic Toxins and Their Role in Kidney Failure. Clin J Am Soc Nephrol. 2021; 16(12):1918-1928. PMC: 8729494. DOI: 10.2215/CJN.02660221. View

Mitchell C, Hornig C, Canaud B . Systematic review to compare the outcomes associated with the modalities of expanded hemodialysis (HDx) versus high-flux hemodialysis and/or hemodiafiltration (HDF) in patients with end-stage kidney disease (ESKD). Semin Dial. 2022; 36(2):86-106. DOI: 10.1111/sdi.13130. View

BABB A, Ahmad S, Bergstrom J, Scribner B . The middle molecule hypothesis in perspective. Am J Kidney Dis. 1981; 1(1):46-50. DOI: 10.1016/s0272-6386(81)80011-x. View

Shroff R, Basile C, van der Sande F, Mitra S . Haemodiafiltration for all: are we CONVINCEd?. Nephrol Dial Transplant. 2023; 38(12):2663-2665. DOI: 10.1093/ndt/gfad136. View

Saito A . Definition of high-performance membranes - from the clinical point of view. Contrib Nephrol. 2011; 173:1-10. DOI: 10.1159/000328938. View

Vernooij R, Bots M, Strippoli G, Canaud B, Cromm K, Woodward M . CONVINCE in the context of existing evidence on haemodiafiltration. Nephrol Dial Transplant. 2022; 37(6):1006-1013. PMC: 9130023. DOI: 10.1093/ndt/gfac019. View

Locatelli F, Karaboyas A, Pisoni R, Robinson B, Fort J, Vanholder R . Mortality risk in patients on hemodiafiltration versus hemodialysis: a 'real-world' comparison from the DOPPS. Nephrol Dial Transplant. 2017; 33(4):683-689. PMC: 5888924. DOI: 10.1093/ndt/gfx277. View

10.

Storr M, Ward R . Membrane innovation: closer to native kidneys. Nephrol Dial Transplant. 2018; 33(suppl_3):iii22-iii27. PMC: 6168921. DOI: 10.1093/ndt/gfy228. View

11.

Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V . Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2008; 20(3):645-54. PMC: 2653681. DOI: 10.1681/ASN.2008060590. View

12.

van Gelder M, Middel I, Vernooij R, Bots M, Verhaar M, Masereeuw R . Protein-Bound Uremic Toxins in Hemodialysis Patients Relate to Residual Kidney Function, Are Not Influenced by Convective Transport, and Do Not Relate to Outcome. Toxins (Basel). 2020; 12(4). PMC: 7232478. DOI: 10.3390/toxins12040234. View

13.

Madero M, Cano K, Campos I, Tao X, Maheshwari V, Brown J . Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor. Clin J Am Soc Nephrol. 2019; 14(3):394-402. PMC: 6419294. DOI: 10.2215/CJN.05240418. View

14.

Meijers B, Vega A, Juillard L, Kawanishi H, Kirsch A, Maduell F . Extracorporeal Techniques in Kidney Failure. Blood Purif. 2023; 53(5):343-357. DOI: 10.1159/000533258. View

15.

Ronco C, Marchionna N, Brendolan A, Neri M, Lorenzin A, Martinez Rueda A . Expanded haemodialysis: from operational mechanism to clinical results. Nephrol Dial Transplant. 2018; 33(suppl_3):iii41-iii47. PMC: 6168809. DOI: 10.1093/ndt/gfy202. View

16.

Sakurai K . Biomarkers for evaluation of clinical outcomes of hemodiafiltration. Blood Purif. 2013; 35 Suppl 1:64-8. DOI: 10.1159/000346364. View

17.

Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P . Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003; 63(5):1934-43. DOI: 10.1046/j.1523-1755.2003.00924.x. View

18.

Blankestijn P, Vernooij R, Hockham C, Strippoli G, Canaud B, Hegbrant J . Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure. N Engl J Med. 2023; 389(8):700-709. DOI: 10.1056/NEJMoa2304820. View

19.

Abe M, Masakane I, Wada A, Nakai S, Nitta K, Nakamoto H . Super high-flux membrane dialyzers improve mortality in patients on hemodialysis: a 3-year nationwide cohort study. Clin Kidney J. 2022; 15(3):473-483. PMC: 8862063. DOI: 10.1093/ckj/sfab177. View

20.

Ward R, Vienken J, Silverstein D, Ash S, Canaud B . Regulatory Considerations for Hemodiafiltration in the United States. Clin J Am Soc Nephrol. 2018; 13(9):1444-1449. PMC: 6140579. DOI: 10.2215/CJN.12641117. View